FDx Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,011
| Closed | -$265K | – | 545 |
|
|
2023
Q4 | $265K | Buy |
+2,011
| New | +$265K | 0.02% | 560 |
|
|
2023
Q2 | – | Sell |
-3,159
| Closed | -$377K | – | 810 |
|
|
2023
Q1 | $377K | Hold |
3,159
| – | – | 0.02% | 483 |
|
|
2022
Q4 | $377K | Sell |
3,159
-329
| -9% | -$39.3K | 0.02% | 483 |
|
|
2022
Q3 | $370K | Sell |
3,488
-1,549
| -31% | -$164K | 0.02% | 483 |
|
|
2022
Q2 | $491K | Sell |
5,037
-576
| -10% | -$56.1K | 0.02% | 483 |
|
|
2022
Q1 | $526K | Buy |
5,613
+2,729
| +95% | +$256K | 0.02% | 490 |
|
|
2021
Q4 | $246K | Sell |
2,884
-2,179
| -43% | -$186K | 0.01% | 771 |
|
|
2021
Q3 | $486K | Buy |
5,063
+621
| +14% | +$59.6K | 0.02% | 524 |
|
|
2021
Q2 | $432K | Buy |
4,442
+167
| +4% | +$16.2K | 0.01% | 547 |
|
|
2021
Q1 | $416K | Buy |
4,275
+1,588
| +59% | +$155K | 0.02% | 516 |
|
|
2020
Q4 | $258K | Buy |
2,687
+312
| +13% | +$30K | 0.01% | 614 |
|
|
2020
Q3 | $228K | Buy |
+2,375
| New | +$228K | 0.01% | 556 |
|